2012•CNS DrugsRequires access

Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder

Marc D. Binder, Weiping Yu, Johan Detraux, Kim Sweers, Ruud van Winkel, Christoph Ulrich Correll

Open publisher page 163 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 163 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Asenapine, Lurasidone, Paliperidone, Medicine, Tolerability, Quetiapine, Bipolar disorder, Atypical antipsychotic

Back to paper search Browse research topics Original source

Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder — Research Paper | ScholarLens